Clinical trials: asthma
Asthma
Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma
Specific Aim: To determine whether a prescription for Inhaled Corticosteroids (ICS) added to standard Emergency Department (ED) discharge therapy for young children with persistent asthma symptoms increases ICS use and improves…
- Trial name
- NCT00294398
- Testing
- ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Children's Hospital of Philadelphia
Asthma
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma.
- Trial name
- SYGMA1 (NCT02149199)
- Testing
- budesonide bid + terbutaline 'as needed'
- Where
- 255 sites in Australia, Brazil and 16 more
- Volunteers
- 3,850 people
- Sponsor
- AstraZeneca
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Phase 2, open-label, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 6 months in subjects with chronic sinusitis with nasal polyps and eosinophilia.
- Trial name
- CS201 (NCT02217332)
- Testing
- dexpramipexole
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Knopp Biosciences
Asthma
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in…
- Trial name
- NCT02141854
- Testing
- FS MDPI, Fp MDPI, Albuterol/salmeterol HFA MDI
- Where
- 154 sites in United States, Canada and 7 more
- Volunteers
- 882 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
- Trial name
- BORA (NCT02258542)
- Testing
- Benralizumab
- Where
- 429 sites in United States, Argentina and 22 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
This is a 12-week treatment, multicenter, open-label, randomized, parallel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, digital health…
- Trial name
- CONNECT1 (NCT03890666)
- Testing
- Albuterol eMDPI DS, albuterol
- Where
- 29 sites in United States
- Volunteers
- 333 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects
This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to…
- Trial name
- NCT02991859
- Testing
- Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Asthma
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests…
- Trial name
- NCT00441441
- Testing
- fluticasone propionate, fluticasone propionate/salmeterol
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Asthma
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent asthma.
- Trial name
- NCT00556673
- Testing
- indacaterol maleate/mometasone furoate, fluticasone proprionate / salmeterol xinafoate
- Where
- 2 sites in France, Germany
- Volunteers
- 31 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs.
- Trial name
- NCT00442117
- Testing
- mometasone furoate dry powder inhaler, Budesonide DPI
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically…
- Trial name
- NIMBLE (NCT04718389)
- Testing
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab
- Where
- 397 sites in United States, Australia and 19 more
- Volunteers
- 1,717 people
- Sponsor
- GlaxoSmithKline
Asthma
A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation
This is a double blind, controlled clinical trail testing whether three doses of 1.25 mg of nebulized levalbuterol in combination with three doses of 0.5mg of nebulized ipratropium will lead to greater bronchodilation than that…
- Trial name
- NCT00583778
- Testing
- ipratropium
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- MetroHealth Medical Center
Asthma
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
- Trial name
- NCT03358147
- Testing
- GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg
- Where
- 232 sites in United States
- Volunteers
- 1,077 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose…
- Trial name
- NCT01396278
- Testing
- Fluticasone propionate, BI 54903
- Where
- 37 sites in United States
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Asthma, Sleep Apnea Syndromes
Service Development: Assessing Non-attendance Rates in Outpatient Clinics
Many studies have shown a high non-attendance rate in hospital outpatient clinics. The investigators have found a non-attendance rate of 25% in their asthma clinics and would like to investigate whether a reminder phone call will…
- Conditions
- Asthma, Sleep Apnea Syndromes, Tuberculosis, COPD
- Trial name
- NCT00129649
- Testing
- Telephone reminder call
- Where
- United Kingdom
- Volunteers
- 504 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Asthma
Role of Eosinophils in the Proliferation of Airway Smooth Muscle (ASM) Cells
Being a key player in Asthma, eosinophils constitute a potential target to interfere with the series of biological events leading to Asthma pathogenesis.
- Trial name
- NCT01082952
- Where
- Saudi Arabia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- King Saud University
Healthy Volunteers, Asthma
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants
GSK3772847, an anti-interleukin (IL) 33-receptor monoclonal antibody, is a novel treatment for asthma. The purpose of this study to evaluate the safety and tolerability, PK and PD of single ascending doses of GSK3772847…
- Trial name
- NCT04366349
- Testing
- melrilimab (GSK3772847) 70 milligram (mg), melrilimab (GSK3772847) 140 milligram (mg)
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when…
- Trial name
- NCT02139644
- Testing
- FS MDPI, Fp MDPI, albuterol/salbutamol
- Where
- 140 sites in United States, Canada and 6 more
- Volunteers
- 787 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.